Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39)Schrijnders, D., Wever, R., Kleefstra, N., Houweling, S. T., van Hateren, K. J. J., de Bock, G. H., Bilo, H. J. G., Groenier, K. H. & Landman, G. W. D., Oct-2016, In : Diabetes obesity & metabolism. 18, 10, p. 973-979 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Aim: To investigate changes in body weight trajectories after the addition of individual sulphonylureas (SUs) to metformin in patients with type 2 diabetes.
Materials and methods: We conducted a retrospective observational cohort study, in a primary care setting in the Netherlands. Patients aged >= 18 years with type 2 diabetes who were included in the ZODIAC cohort between 1998 and 2012 and who received metformin monotherapy at inclusion (n = 29 195), and had used metformin as monotherapy for at least 1 year before receiving dual therapy through the addition of an SU for at least 1 year were eligible for inclusion. The primary outcome was within-drug yearly change in body weight after receiving add-on therapy with individual SUs during 5 years of follow-up. The secondary outcome was within-drug yearly change in glycated haemoglobin (HbA1c). Annual changes in weight and HbA1c were estimated with linear mixed models, adjusted for age, gender and diabetes duration.
Results: A total of 2958 patients were included. No significant weight changes were observed within and between any of the individual SUs after treatment intensification (p = 0.24). In addition, no significant difference in weight between the add-on therapy combinations was observed (p = 0.26). The average HbA1c the year before intensification was 7.2% (55 mmol/mol) and dropped below 7.0% (53 mmol/mol) the year after.
Conclusions: In patients with type 2 diabetes treated in primary care, strict glycaemic control can be maintained with SUs used as add-on therapy to metformin, without the offset of relevant weight changes.
|Number of pages||7|
|Journal||Diabetes obesity & metabolism|
|Publication status||Published - Oct-2016|
- blood glucose, body weight, diabetes mellitus type 2, humans, metformin, prospective studies, sulphonylurea compounds, TYPE-2 DIABETES-MELLITUS, GLYCEMIC CONTROL, CONTROLLED-TRIAL, DOUBLE-BLIND, MASS INDEX, THERAPY, EFFICACY, INSULIN, COMBINATION, MONOTHERAPY